Summary

The FDA is halting production of compounded tirzepatide, a cheaper alternative to Eli Lilly’s obesity drug Zepbound, as it declares the shortage over.

Patients who relied on compounded versions, like fear losing access due to high brand-name costs. Some are stockpiling, while others consider risky gray-market sources.

Compounding pharmacies will stop production but can sell remaining stock.

Critics argue that Eli Lilly’s discount programs are insufficient, leaving many unable to afford the branded medication.